CAJ | 학술논문

目的：评价通络明目胶囊治疗糖尿病视网膜病变的有效性和安全性。方法：采用平行对照、随机、双盲临床试验方法，将146例受试者随机分为试验组和对照组，分别服用通络明目胶囊和羟苯磺酸钙胶囊治疗，疗程均为12周。结果：疾病综合疗效试验组为73.91%，对照组为72.31%；中医证候疗效试验组为89.86%；对照组为73.85%。2组比较疾病综合疗效差异无统计学意义(P＞0.05)。结论：通络明目胶囊治疗糖尿病视网膜病变疗效与羟苯磺酸钙胶囊相当，且不良反应发生率低。
목적：평개통락명목효낭치료당뇨병시망막병변적유효성화안전성。방법：채용평행대조、수궤、쌍맹림상시험방법，장146례수시자수궤분위시험조화대조조，분별복용통락명목효낭화간분광산개효낭치료，료정균위12주。결과：질병종합료효시험조위73.91%，대조조위72.31%；중의증후료효시험조위89.86%；대조조위73.85%。2조비교질병종합료효차이무통계학의의(P＞0.05)。결론：통락명목효낭치료당뇨병시망막병변료효여간분광산개효낭상당，차불량반응발생솔저。
Objective:To evaluate the safety and effectiveness of TongLuo MingMu capsule for the treatment of diabetic retinopathy (DR). Method:All 146 patients were randomized into the experiment group and the control group through parallel controlled, randomized, double-blind clinical trial. Both groups took TongLuo MingMu capsule and calcium dobesilate capsule respectively, the therapy lasted 12 weeks. Result:Comprehensive effect of the experiment group was 73.91%, higher than 72.31% of the control group; TCM effects of both groups were 89.86%and 73.85%. The difference had no statistical meaning between both groups in comprehensive effects of the disease (P>0.05). Conclusion:Curative effects of TongLuo MingMu capsule are notable in treating DR, similar to calcium dobesilate capsule but with lower incidence of adverse reaction.